OnKure Therapeutics, Inc. (OKUR)
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
OnKure Therapeutics, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 40.50M shares outstanding
USOnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer.
The company focuses on developing selective inhibitors of histone deacetylases.
Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors.
The company was incorporated in 2011 and is based in Boulder, Colorado.
Leadership
Andrew Phillips, Ph.D.
Director and Chairperson of the Board
Edward T. Mathers
Director
Isaac Manke
Senior VP of Business Development & Director
Isaac Manke, Ph.D.
Director
Employees
46
Country
US
Sector
Healthcare
Website
onkuretherapeutics.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Saccomano Nicholas A | President and CEO | Sale | 87 | $258.755 | Sep 21, 2026 |
 Leverone Jason A. | Chief Financial Officer | Sale | 302 | $898.208 | Sep 21, 2026 |
 Mathers Edward T | Director | Grant/Award | 22.4K | -- | Aug 7, 2026 |
 GREY MICHAEL G | Director | Grant/Award | 22.4K | -- | Aug 7, 2026 |
 Carruthers R Michael | Director | Grant/Award | 22.4K | -- | Aug 7, 2026 |
| Leverone Jason A. | Chief Financial Officer | Grant/Award | 130.6K | -- | Aug 7, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
The Carlyle Group Inc. 2 · also on 13F· may incl. warrants· filed Oct 2024 | 27.3M | 2.2% as filed | 13D |
RA CAPITAL MANAGEMENT, L.P. | 4.0M | 9.9% | 13F |
 AI Biotechnology LLC 10% Owner | 4.0M | 9.9% | FORM 4 |
BVF INC/IL | 3.2M | 8.0% | 13F |
TANG CAPITAL PARTNERS, LP · may incl. warrants· reaffirmed 13G/A Nov 2024 | 2.9M | 7.3% | 13G |
ACORN CAPITAL ADVISORS, LLC | 2.8M | 7.0% | 13F |
Coastlands Capital LP · joint filing· may incl. warrants· filed Oct 2026 | 2.7M | 6.7% | 13G |
StepStone Group LP | 2.7M | 6.6% | 13F |
ADAR1 Capital Management, LLC · also on 13F· joint filing· may incl. warrants· filed May 2026 | 2.4M | 6.0% | 13G |
ADAR1 Capital Management, LLC | 2.2M | 5.5% | 13F |
Insiders
- Saccomano Nicholas APresident and CEO
- Leverone Jason A.Chief Financial Officer
- Mathers Edward TDirector
- GREY MICHAEL GDirector
- Carruthers R MichaelDirector
- Manke IsaacDirector
- Ratcliffe LiamDirector
- Phillips Andrew JohnDirector
- Jansen Valerie MalyvanhDirector
- Hartley DylanChief Scientific Officer
based on 40.50M shares outstanding
US30d Avg
476.12K
60d Avg
314.92K
90d Avg
254.81K